JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB257944

Human EXOC2 knockout HeLa cell lysate

Human EXOC2 knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

EXOC2 KO cell lysate available now. KO validated. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon3 and 2 bp insertion in exon3.

別名を表示する

EXOC2_HUMAN, Exocyst complex component 2, Exocyst complex component Sec5, FLJ11026, SEC5, SEC5 like 1, SEC5L1, Sec5p

3 Images
Western blot - Human EXOC2 knockout HeLa cell lysate (AB257944)
  • WB

Lab

Western blot - Human EXOC2 knockout HeLa cell lysate (AB257944)

Lane 1 : Wild-type HeLa cell lysate (20μg)
Lane 2 : EXOC2 knockout HeLa cell lysate (20μg)
Lane 3 : SH-SY5Y cell lysate (20μg)
Lane 4 : Daudi cell lysate (20μg)
Lanes 1- 4 : Merged signal (red and green). Green - ab140620 observed at 104 kDa. Red - loading control, ab8245 observed at 37 kDa.
ab140620 Recombinant Anti-EXOC2 antibody [EPR9420] was shown to specifically react with EXOC2 in wild-type HeLa cells in western blot. The band observed in the knockout cell line ab265839 (knockout cell lysate ab257944) lane below 104kDa may represent truncated forms and cleaved fragments. This has not been investigated further. Wild-type and EXOC2 knockout samples were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. ab140620 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4°C at 1 in 1000 and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-EXOC2 antibody [EPR9420] (<a href='/products/primary-antibodies/exoc2-antibody-epr9420-ab140620'>ab140620</a>) at 1000 µg

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

EXOC2 knockout HeLa cell lysate at 20 µg

Lane 3:

SH-SY5Y cell lysate at 20 µg

Lane 4:

Daudi cell lysate at 20 µg

Predicted band size: 104 kDa

Observed band size: 104 kDa

false

Sanger Sequencing - Human EXOC2 knockout HeLa cell lysate (AB257944)
  • Sanger seq

Unknown

Sanger Sequencing - Human EXOC2 knockout HeLa cell lysate (AB257944)

Allele-1 : 1 bp insertion in exon3

Sanger Sequencing - Human EXOC2 knockout HeLa cell lysate (AB257944)
  • Sanger seq

Unknown

Sanger Sequencing - Human EXOC2 knockout HeLa cell lysate (AB257944)

Allele-2 : 2 bp insertion in exon3

Key facts

細胞タイプ

HeLa

生物種

Human

組織

Cervix

ノックアウト検証方法

Sanger Sequencing

ノックアウト変異

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon3 and 2 bp insertion in exon3.

疾病

Adenocarcinoma

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p>Western blot data indicates that the CRISPR gene edit may have resulted in a truncation of the protein of interest. Please see data images.</p>" } } }
style
left-column

製品の詳細

Western blot data indicates that the CRISPR gene edit may have resulted in a truncation of the protein of interest. Please see data images.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

style
left-column

製品内容

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab257944-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human EXOC2 knockout HeLa cell lysate", "number":"AB257944-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB257944-CMP02", "productcode":"" } ] } } }
style
left-column

出荷温度及び保存条件

遺伝子名
EXOC2
遺伝子編集のタイプ
Knockout
遺伝子編集の方法
CRISPR technology
ノックアウト検証方法
Sanger Sequencing
出荷温度
Ambient - Can Ship with Ice
短期保存温度
-20°C
長期保存温度
-20°C
style
left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

The exocyst complex component 2 also known as EXOC2 or SEC5 is an important protein involved in vesicle trafficking. EXOC2 has an estimated mass of around 105 kDa. It is widely expressed in various tissues highlighting its broad significance in cellular processes. Its primary role is to participate in the tethering of secretory vesicles to specific sites on the plasma membrane aiding in processes like cell migration and growth.
Biological function summary

EXOC2 acts as a fundamental part of the exocyst complex which comprises eight proteins. This complex orchestrates vesicle targeting and tethering during exocytosis a process essential for maintaining cell surface area and membrane protein composition. Unlike other vesicle trafficking complexes the exocyst shows significant specificity for certain vesicles and localization contributing to the precision of membrane-associated functions.

Pathways

EXOC2 joins key pathways like the insulin signaling pathway and the regulation of actin cytoskeleton. In the insulin signaling pathway EXOC2 integrates with components such as the protein Rab11 to mediate glucose transporter vesicle trafficking impacting glucose uptake. In the regulation of the actin cytoskeleton it interacts with actin-related proteins to influence cell shape and motility.

Connection with EXOC2 influences conditions such as cancer and diabetes. Abnormal EXOC2 expression links to various cancers often through disruptions in cellular trafficking and signal transduction. The interplay with diabetes arises partly through its role in insulin-mediated processes with proteins like Rab11 that affect glucose homeostasis. These associations highlight the potential for EXOC2 as a therapeutic target in these diseases.
style
left-column

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

style
left-column

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

style
left-column

製品プロトコール

style
left-column
style
left-column
style
right-column

組合せ製品

Primary Antibodies

AB140620

Anti-EXOC2 antibody [EPR9420]

RabMAb|Recombinant

Flow Cytometry (Intracellular) - Anti-EXOC2 antibody [EPR9420] (AB140620)

  • 5
  • 1
Cell Lines & Lysates

AB265839

Human EXOC2 knockout HeLa cell line

Advanced Validation

Western blot - Human EXOC2 knockout HeLa cell line (AB265839)

  • 0
  • 0

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com